The promising drug candidate indazolium trans‐[tetrachlorobis (1H‐indazole) ruthenate
(III)](KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review …

The well-developed synthetic chemistry of ruthenium, particularly with ammine, amine and
imine ligands, provides for many approaches to innovative new metallopharmaceuticals …

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of
the metal, its oxidation state, the types and number of coordinated ligands and the …

Since the discovery of cis-platinum, many transition metal complexes have been
synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based …

Abstract Purpose: NAMI-A {H2Im [trans-RuCl4 (DMSO) HIm] or imidazolium-trans-DMSO-
imidazole-tetrachlororuthenate} is a novel ruthenium-containing compound that has …

Indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A) is just the
second ruthenium-based anticancer agent after NAMI-A which was developed to the stage …

Ruthenium complexes exhibit a broad variety of biological and biomedical activities
including anticancer efficiency. The reason is that the octahedral bonding of both Ru (II) and …

The antitumor activity of the organometallic ruthenium (II)− arene complexes, RuCl2 (η6-
arene)(PTA),(arene= p-cymene, toluene, benzene, benzo-15-crown-5, 1-ethylbenzene-2, 3 …

There is no doubt about the success of precious metals in the clinic, with, for example,
platinum compounds being widely used in the treatment of cancer, silver compounds being …

Despite the resounding success of cisplatin and closely related platinum antitumor agents, 1-
3 the movement of other transition-metal antitumor agents toward the clinic has been …